ERA4Health: Trials4Health 2026

The aim of this call is to support randomized interventional multi-country Investigator-Initiated Clinical Studies that are designed as pragmatic comparative-effectiveness studies and/or repurposing studies. It is also to encourage and enable transnational collaboration between clinical/public health research teams.

Proposals should take into account the following:

• The proposed study needs to be a pragmatic comparative effectiveness trial and/or a drug repurposing trial, designed as Phase III randomized interventional trial
• In case of comparative effectiveness trials, these must compare the use of currently approved or existing healthcare interventions used in clinical practice in Europe
• In case of comparative effectiveness trials, these must consider existing, approved healthcare interventions, which could include but would not be limited to: diagnosis, screening, prevention and treatment interventions
• In case of drug repurposing trials, the aim shall be to explore a new identification of an approved off-patent medication (excluding clinical studies with a commercial purpose are excluded, due to the call being supported by public funding)
• These interventions shall have high public relevance in at least one of these specific diseases or conditions:
  • Cardiovascular disease
  • Metabolic disorders
  • Autoimmune diseases

Deadlines:

• Pre-proposal submission: 27 January 2026
• Full proposal submission: June 17, 2026